Long COVID is not officially classified as an autoimmune disease, but it shares striking features with one. Researchers have found autoantibodies, chronic inflammation, and immune dysfunction in people with Long COVID that closely mirror patterns seen in established autoimmune conditions. The emerging picture is that autoimmunity is likely one of several overlapping mechanisms driving symptoms, rather than the sole explanation.
Why Autoimmunity Keeps Coming Up
The hallmark of autoimmune disease is the body producing antibodies that attack its own tissues. In Long COVID, researchers have consistently found exactly that. A particularly important group of autoantibodies targets receptors on the surface of cells that regulate the autonomic nervous system, the part of your nervous system that controls heart rate, blood pressure, digestion, and other functions you don’t consciously manage.
These autoantibodies appear to physically block the receptors, preventing normal signaling molecules from doing their jobs. One study in the International Journal of Molecular Sciences identified a cluster of these antibodies that correlated directly with specific Long COVID symptoms: palpitations, drops in blood pressure upon standing, brain fog, exercise intolerance, and fatigue. Antibodies targeting one receptor in particular, the beta-2 adrenergic receptor, appear strongly linked to symptom development. That receptor is found across immune cells, blood vessel linings, and nerve cells, which helps explain why blocking it could produce such widespread problems.
Autoantibodies targeting the heart, cell nuclei, and other structures have also been identified in Long COVID patients. The nuclear antibodies correlate with fatigue and shortness of breath, two of the most common complaints.
How It Differs From Classic Autoimmune Disease
In diseases like lupus or type 1 diabetes, the immune system zeroes in on specific organs or tissues and progressively destroys them. Long COVID doesn’t follow that pattern cleanly. Symptoms fluctuate, affect multiple body systems simultaneously, and often occur without visible structural damage to organs. The autoantibodies found so far don’t attack a single tissue the way anti-insulin antibodies destroy pancreatic cells in type 1 diabetes. Instead, they disrupt signaling across many systems at once.
This is why some researchers describe Long COVID as having “autoimmune features” rather than calling it an autoimmune disease outright. The immune system is clearly misbehaving, but the pattern looks more like widespread regulatory dysfunction than a targeted assault on one part of the body.
Autoimmunity Is Not the Only Mechanism
Several other biological processes appear to be happening alongside, or even feeding into, the autoimmune response. The current understanding is that Long COVID likely involves multiple overlapping drivers, and different patients may have different dominant mechanisms.
Viral persistence. Fragments of the SARS-CoV-2 virus, or even active virus, may linger in certain tissues for months after the initial infection. These tissues can become sheltered from the immune system, acting as reservoirs that keep triggering inflammation. The ongoing immune response to these viral remnants may also be what generates the autoantibodies in the first place, through a process called molecular mimicry, where parts of the virus resemble the body’s own proteins closely enough to confuse the immune system.
Microclots. The SARS-CoV-2 spike protein can trigger the formation of abnormal, clot-resistant clumps of fibrin (the protein that forms the scaffold of blood clots). These microclots range from 1 to 200 micrometers in size, large enough to physically block capillaries and restrict oxygen delivery to tissues. Researchers have argued that this oxygen deprivation alone could explain many Long COVID symptoms, from fatigue and brain fog to shortness of breath. These microclots also trap other proteins and may themselves generate new autoantibodies, creating a feedback loop.
T-cell exhaustion. The immune cells responsible for clearing infections and keeping the immune system in check show signs of burnout in Long COVID patients. Specialized studies have found that certain T cells remain in an exhausted state for up to 12 months after infection, with reduced ability to multiply or respond to threats. These worn-out cells coexist with elevated inflammatory markers, suggesting a cycle where chronic inflammation exhausts immune cells, and exhausted immune cells fail to resolve the inflammation.
The ME/CFS Connection
One of the most telling clues about Long COVID’s autoimmune nature comes from its near-identical immune profile to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition that has long been suspected of having autoimmune roots. When researchers compared blood samples from the two groups, they found no significant differences in any of the tested biomarkers.
Both conditions showed reduced counts of lymphocytes, a key category of white blood cell, along with lower numbers of natural killer cells and CD8+ T cells (the cells that destroy infected or abnormal cells). Both groups had elevated levels of the same inflammatory molecules. The ratio of helper T cells to killer T cells was similarly skewed in both conditions, a pattern that could serve as a marker for tracking disease severity. The same autoantibodies targeting autonomic nervous system receptors show up in both Long COVID and ME/CFS, further reinforcing that these may be variations on the same underlying process.
Who Gets It Mirrors Autoimmune Patterns
Autoimmune diseases disproportionately affect women, with roughly 80% of autoimmune disease patients being female across many conditions. Long COVID follows a strikingly similar pattern. While men tend to have more severe acute COVID-19 infections and higher mortality during the initial illness, women are more likely to develop Long COVID afterward. This sex-based split is consistent with what immunologists would expect if autoimmune mechanisms were a major driver.
No Definitive Test Exists Yet
Despite all the autoantibodies and inflammatory markers researchers have identified, there is no validated blood test that can confirm Long COVID or determine whether a given patient’s symptoms are autoimmune-driven. Diagnostic characterization remains challenging because the condition affects so many body systems and the biomarkers identified so far haven’t been standardized for clinical use. Long COVID is still diagnosed based on symptom history and the exclusion of other conditions.
Treatment Trials Are Testing the Theory
One of the most direct ways to test whether Long COVID is autoimmune is to treat it with therapies that work for autoimmune diseases and see if symptoms improve. The NIH-funded RECOVER trial is currently doing exactly that, testing intravenous immunoglobulin (IVIG), a treatment commonly used for autoimmune and inflammatory conditions, in Long COVID patients with autonomic dysfunction. Participants receive weekly infusions over nine months in a blinded trial, meaning neither they nor the research team know who is getting the real treatment versus a placebo. Results from this trial will provide some of the strongest evidence yet for or against the autoimmune hypothesis.
The fact that Long COVID shares autoantibody profiles, immune cell patterns, inflammatory markers, and demographic trends with established autoimmune conditions makes autoimmunity one of the most compelling explanations. But calling it purely an autoimmune disease would oversimplify what appears to be a condition where viral persistence, clotting abnormalities, and immune dysfunction all feed into each other. For patients, the practical distinction may matter less than the treatments that emerge from understanding each of these pathways.